缬沙坦对稳定型心绞痛伴高血压患者血清MMP-1、MMP-9及TIMP-1水平的影响

The Effect of Valsartan on Serum Level of Matrix Metalloprotease-1,Matrix metalloprotease-9 and Tissue Inhibitors of Matrix Metalloproteinase-1 in Patients with Stable Angina Pectoris and Essential Hypertension

目的探讨稳定型心绞痛(SAP)伴高血压患者经缬沙坦治疗前后血清明胶酶(MMP1,MMP9)、基质金属蛋白酶组织抑制因子1(TIMP1)水平,明确SAP伴高血压患者动脉粥样硬化斑块的稳定性。方法选择SAP患者30例,SAP伴高血压Ⅰ级患者66例,30例健康人作为对照。随机将SAP伴高血压患者分成缬沙坦治疗组(36例)及常规治疗组(30例),比较各组患者血清MMP1、MMP9和TIMP1水平变化。结果SAP伴高血压、SAP、健康对照组三组之间MMP1、MMP9和TIMP1水平比较,差异有统计学意义,缬沙坦治疗组与常规治疗组治疗后血清MMP1、MMP9和TIMP1水平相比,差异有统计学意义。结论SAP伴高血压患者血清MMP1、MMP9增高及TIMP1降低可能导致粥样斑块破裂不稳定,缬沙坦可降低该类患者血清MMP1、MMP9水平,升高TIMP1水平,从而起到稳定斑块的作用。

Objective To obseve the effect of valsartan of serum levels of matrix metalloprotease-1, matrix metalloprotease-9 （MMP-9） and tissue inhibitors of matrix metalloproteinase-1 （TIMP-1） in patients with stable angina pectoris （SAP）. Methods 30 patients with SAP,66 patients with SAP and essential hypertension class 1 were selected for study while 30 healthy individuals were selected as a control;the 66 patients with SAP and essential hypertension class I were randomly divided into two groups;valsartan treatment group and regular treatment group; the serum levels of MMP-1, MMP-9 and TIMP-1 were compared. Results There was a significant difference in serum levels of MMP-1, MMP-9 and TIMP-1 among the groups, and the levels were different between valsartan treatment group and regular treatment group after treatment in patients with SAP and essential hypertension class I. Conclusions Plaque disruption may be related to the increased serum level of MMP-9 and the decreased serum level of TIMP- 1 ;Valsaretan can decrease serum level of MMP-1 ,MMP-9 and increase serum level of TIMP-1 in patients with SAP and essential hypertension class I;Valsartan may be of beneficial effect in steadying the plaque.